Identifying Novel Molecular Structures for Advanced Melanoma by Ligand-Based Virtual Screening

Journal of Chemical Information and Modeling

Volumn 49, Issue 6, 2009, Pages 1420-1427

  Wang, Zhao ^a   Lu, Yan ^a   Seibel, William ^b   Miller, Duane D ^a   Li, Wei ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b UNIVERSITY OF CINCINNATI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL CULTURE; DERMATOLOGY; DIGITAL LIBRARIES; LIGANDS; MOLECULES; ONCOLOGY;

ANTICANCER ACTIVITIES; ANTICANCER COMPOUNDS; COMPOUND LIBRARIES; MOLECULAR SCAFFOLDS; SCREENING METHODS; STRUCTURAL MODIFICATIONS; STRUCTURE ACTIVITY RELATIONSHIPS; VIRTUAL SCREENING;

LEAD COMPOUNDS;

ANTINEOPLASTIC AGENT; LIGAND;

ANIMAL; ARTICLE; CHEMISTRY; COMPUTER INTERFACE; COMPUTER PROGRAM; DRUG SCREENING; HUMAN; IC 50; MELANOMA; METHODOLOGY; MOUSE; PATHOLOGY; REPRODUCIBILITY; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DRUG EVALUATION, PRECLINICAL; HUMANS; INHIBITORY CONCENTRATION 50; LIGANDS; MELANOMA; MICE; REPRODUCIBILITY OF RESULTS; SOFTWARE; USER-COMPUTER INTERFACE;

EID: 67650092004     PISSN: 15499596     EISSN: 1549960X     Source Type: Journal    
DOI: 10.1021/ci800445a     Document Type: Article

References (21)

1. Gray-Schopfer, V.; Wellbrock, C.; Marais, R. Melanoma biology and new targeted therapy. Nature 2007, 445, 851-857.
2. Carlson, J. A.; Ross, J. S.; Slominski, A.; Linette, G.; Mysliborski, J.; Hill, J.; Mihm, M., Jr. Molecular diagnostics in melanoma. J. Am. Acad. Dermatol. 2005, 52, 743-775.
3. Jemal, A.; Tiwari, R. C.; Murray, T.; Ghafoor, A.; Samuels, A.; Ward, E.; Feuer, E. J.; Thun, M. J. Cancer statistics, 2004. Ca-Cancer J. Clin. 2004, 54, 8-29.
4. Ries LAG, M. D.; Krapcho, M.; Stinchcomb, D. G.; Howlader, N.; Horner, M. J.; Mariotto, A.; Miller, B. A.; Feuer, E. J.; Altekruse, S. F.; Lewis, D. R.; Clegg, L.; Eisner, M. P.; Reichman, M. SEER Cancer Statistics Review, 1975-2005; National Cancer Institute: Bethesda, MD, 2007.
5. Lucas, R. Global Burden of Disease of Solar Ultraviolet Radiation; News Release No. 13; World Health Organization: Geneva, Switzerland, 2006.
6. Chapman, P. B.; Einhorn, L. H.; Meyers, M. L.; Saxman, S.; Destro, A. N.; Panageas, K. S.; Begg, C. B.; Agarwala, S. S.; Schuchter, L. M.; Ernstoff, M. S.; Houghton, A. N.; Kirkwood, J. M. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J. Clin. Oncol. 1999, 17, 2745-2751.
7. Eton, O.; Legha, S. S.; Bedikian, A. Y.; Lee, J. J.; Buzaid, A. C.; Hodges, C.; Ring, S. E.; Papadopoulos, N. E.; Plager, C.; East, M. J.; Zhan, F.; Benjamin, R. S. Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial. J. Clin. Oncol. 2002, 20, 2045-2052.
8. Mandara, M.; Nortilli, R.; Sava, T.; Cetto, G. L. Chemotherapy for metastatic melanoma. Expert Rev. Anticancer Ther. 2006, 6, 121-130.
9. Kaufmann, R.; Spieth, K.; Leiter, U.; Mauch, C.; von den Driesch, P.; Vogt, T.; Linse, R.; Tilgen, W.; Schadendorf, D.; Becker, J. C.; Sebastian, G.; Krengel, S.; Kretschmer, L.; Garbe, C.; Dummer, R. Temozolomide in combination with interferon-alfa versus Temozolomide alone in patients with advanced metastatic melanoma: a randomized, phase III, multicenter study from the Dermatologic Cooperative Oncology Group. J. Clin. Oncol. 2005, 23, 9001-9007.
10. Anderson, C. M.; Buzaid, A. C.; Legha, S. S. Systemic treatments for advanced cutaneous melanoma. Oncology (Williston Park) 1995, 9, 1149-1158.
11. Eggermont, A. M.; Kirkwood, J. M. Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years? Eur. J. Cancer 2004, 40, 1825-1836.
12. Atallah, E.; Flaherty, L. Treatment of metastatic malignant melanoma. Curr. Treat. Options Oncol. 2005, 6, 185-193.
13. Young, A. M.; Marsden, J.; Goodman, A.; Burton, A.; Dunn, J. A. Prospective randomized comparison of dacarbazine (DTIC) versus DTIC plus interferon-alpha (IFN-alpha) in metastatic melanoma. Clin. Oncol. (R Coll Radiol) 2001, 13, 458-465.
14. Serrone, L.; Zeuli, M.; Sega, F. M.; Cognetti, F. Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview. J. Exp. Clin. Cancer Res. 2000, 19, 21-34.
15. Lu, Y.; Li, C. M.; Wang, Z.; Ross, C. R., 2nd; Chen, J.; Dalton, J. T.; Li, W.; Miller, D. D. Discovery of 4-substituted methoxybenzoyl-aryl-thiazole as novel anticancer agents: synthesis, biological evaluation, and structure-activity relationships. J. Med. Chem. 2009, 52, 1701-1711.
16. Zhou, D.; Alelyunas, Y.; Liu, R. Scores of extended connectivity fingerprint as descriptors in QSPR study of melting point and aqueous solubility. J. Chem. Inf. Model. 2008, 48, 981-987.
17. Yoon, S.; Smellie, A.; Hartsough, D.; Filikov, A. Surrogate docking: Structure-based virtual screening at high throughput speed. J. Comput.-Aided Mol. Des. 2005, 19, 483-497.
18. Hert, J.; Willett, P.; Wilton, D. J.; Acklin, P.; Azzaoui, K.; Jacoby, E.; Schuffenhauer, A. Comparison of topological descriptors for similarity-based virtual screening using multiple bioactive reference structures. Org. Biomol. Chem. 2004, 22, 3256-3266.
19. Shellman, Y. G.; Ribble, D.; Miller, L.; Gendall, J.; Vanbuskirk, K.; Kelly, D.; Norris, D. A.; Dellavalle, R. P. Lovastatin-induced apoptosis in human melanoma cell lines. Melanoma Res. 2005, 15, 83-89.
20. Li, W.; Lu, Y.; Wang, Z.; Dalton, J. T.; Miller, D. D. Synthesis and antiproliferative activity of thiazolidine analogs for melanoma. Bioorg. Med. Chem. Lett. 2007, 17, 4113-4117.
21. Li, W.; Wang, Z.; Gududuru, V.; Zbytek, B.; Slominski, A. T.; Dalton, J. T.; Miller, D. D. Structure-activity relationship studies of arylthi-azolidine amides as selective cytotoxic agents for melanoma. Anticancer Res. 2007, 27, 883-888.